3M signs licensing agreement with Avant

Under the agreement, 3M will provide its patented toll-like receptor (TLR) agonist compounds to Celldex for an undisclosed licensing fee, milestones and royalties.

3M’s patented TLR immune response modifier compounds, which may be useful as vaccine adjuvants, will be used by Celldex to develop new vaccine products. Once commercialized, Celldex will pay 3M royalty usage fees for IRM compounds.

Tibor Keler, chief scientific officer of Celldex, said: “This license agreement provides a great opportunity to combine synergistic technologies designed to treat various cancers and infectious diseases. We are very pleased to enter into this relationship with 3M and look forward to pursuing our clinical studies using 3M’s unique TLR agonists.”